GLPwatch
Papers (10389)
Page 144 of 174, ranked by citation count.
- Gliptins, exenatide, liraglutide: "intestinal obstruction".
- JNK3 regulates β cell responses to incretins in human islets and mouse models.
- Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.
- Depot-specific differences and heterogeneity of adipose-derived stem cells in diet-induced obesity.
- GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study.
- Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.
- Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study.
- Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
- Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
- Functional enhancement of transplanted islets by Extendin-4.
- Role of glucagon-like peptide-1 receptor agonists in pediatric obesity and metabolic dysfunction associated steatotic liver disease.
- [Tirzepatide (Mounjaro®) : a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes].
- Exploratory safety investigations in normal, freely moving Göttingen Minipigs using telemetry: Pharmacological validation.
- [Treatment strategy for elderly diabetic patient with insulin or GLP-1 receptor agonist].
- Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database.
- Gateways to clinical trials.
- A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke-Highlights From the AAIC.
- The Obesity Drug Revolution: New Frontiers in Pharmacotherapy.
- Comments to the Editor Concerning the Paper Entitled "Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4" Mohamed Abd Elaziz Wassef et al.
- Comparative study of dulaglutide single-use pen Ateos versus insulin degludec FlexTouch on learning and mock administration time in Japanese patients with type 2 diabetes mellitus - a <i>post-hoc</i> analysis.
- Acute Duodenal Ulcer Perforation Following Tirzepatide Treatment: A Case Report.
- Vitreous hemorrhage in a patient on tirzepatide: Coincidence or drug induced?
- Tirzepatide for Lipodystrophy.
- Effectiveness and safety of lixisenatide for treatment of diabetes in the real world: data from the Monitoring Registry in a Real-Life Cohort in the Czech and Slovak Republic.
- [Exendin-4 promotes paracrine action of adipose-derived stem cells through PI3K/Akt signaling pathways].
- Tirzepatide-Induced Liver Injury: A Rare Complication.
- Tirzepatide counteracts brown adipose tissue whitening, inflammation, and mitochondrial dysfunction in estrogen-deficient obese diabetic mice.
- Use (and Potential for Abuse) of Glucagon-Like Peptide-1 Medications Among Individuals with Eating Disorders: Empirical Review and Clinical Guidance.
- Adolescent bariatric surgery-a survey of referring practitioners.
- Differential effects of the anti-obesity drug tirzepatide on adipose tissues: Brown fat as a key target.
- Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis.
- Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study.
- Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis.
- Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study.
- The effects of the GLP1 analog liraglutide on allodynia and motor coordination in peripheral neuropathy induced by a chemotherapeutic agent, cisplatin.
- Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
- Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population.
- Semaglutide: A New Medical Swiss Army Knife?
- Redefining peptide therapeutics with semaglutide.
- [Diabetic ketoacidosis after switching insulin for exenatide].
- Semaglutide and Cardiovascular Outcomes. Reply.
- A Case of Pulmonary Hemorrhage, Supratherapeutic International Normalized Ratio (INR), and Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: Unmasking a Potential Link to Tirzepatide.
- Mapping the global research landscape of tirzepatide: a bibliometric analysis of trends, collaborations, and emerging themes in obesity and diabetes managements.
- Management of Obesity in Psoriasis Consultations.
- Impact of oral semaglutide on quality of life and metabolic parameters in patients with type 2 diabetes mellitus: A multicenter observational study.
- Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis.
- Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols.
- ▾ Liraglutide for weight management.
- Navigating Glucagon-Like Peptide Receptor Agonist Reinitiation Amid Access Barriers: An Adverse Drug Event Case Report.
- Validation of a Questionnaire for Assessing the Emotional Impact of Treatment for Type 2 Diabetes.
- Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial.
- [Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)].
- Person-centered choice of anti-obesity pharmacotherapy.
- Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3.
- Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis.
- Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes.
- Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes.
- Pharmacist-led management of GLP-1 and GIP/GLP-1 receptor agonists in type 2 diabetes mellitus.
- Short-term effects of liraglutide and semaglutide on weight gain and adiposity by rats fed a Western diet.
- Effects from treating moderate- to high-risk obesity patients with anti-obesity medication from a societal perspective.